Wellington Management Group LLP lowered its position in Zenas Biopharma Inc (NASDAQ:ZBIO - Free Report) by 24.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,135,289 shares of the company's stock after selling 366,139 shares during the period. Wellington Management Group LLP owned approximately 2.72% of Zenas Biopharma worth $9,172,000 as of its most recent filing with the Securities & Exchange Commission.
Zenas Biopharma Trading Up 0.3%
Shares of ZBIO stock traded up $0.03 during trading hours on Wednesday, hitting $9.55. 102,829 shares of the company's stock were exchanged, compared to its average volume of 181,818. The company has a market capitalization of $399.51 million and a price-to-earnings ratio of -2.69. The business's 50 day moving average price is $9.39. Zenas Biopharma Inc has a fifty-two week low of $5.83 and a fifty-two week high of $26.25.
Zenas Biopharma (NASDAQ:ZBIO - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.35. The business had revenue of $10.00 million for the quarter, compared to analyst estimates of $5.00 million.
Analysts Set New Price Targets
A number of equities research analysts recently commented on ZBIO shares. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Zenas Biopharma in a research report on Friday, May 16th. Wedbush reissued an "outperform" rating and issued a $35.00 price target on shares of Zenas Biopharma in a report on Thursday, May 15th. Finally, Guggenheim reissued a "buy" rating and issued a $45.00 price target on shares of Zenas Biopharma in a report on Wednesday, March 12th.
Get Our Latest Analysis on ZBIO
Zenas Biopharma Company Profile
(
Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Further Reading
Before you consider Zenas Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas Biopharma wasn't on the list.
While Zenas Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
